Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

Frank Zhang returns to Legend 

Plus Protano named CFO at Alltrna, and updates from Laronde, Xentria and more

August 5, 2022 12:45 AM UTC

Two years after the Chinese authorities placed him under “residential surveillance,” former Legend Biotech Corp. (NASDAQ:LEGN) Chairman and CEO Frank Zhang is returning to the company as chairman. Zhang, who is the company’s founding CEO and co-founder and former chair of its parent GenScript Biotech Corp. (HKEX:1548), replaces Ye “Sally” Wang, who will remain on the board. The company also appointed Tomas Heyman and Li Mao to the board, as independent directors. Heyman was president of the corporate venture capital group of Johnson & Johnson (NYSE:JNJ) and Mao is CMO of SciClone Pharmaceuticals Holdings Ltd. (HKEX:6600).

Flagship Pioneering portfolio company Alltrna hired Joanne Protano as CFO. Protano joins from Rubius Therapeutics Inc. (NASDAQ:RUBY), where she was SVP of finance and operations. Before that, she was SVP of finance, new ventures at Flagship. Alltrna is building on recent mRNA momentum with a platform designed to uncover the therapeutic potential of tRNA and turn it into an entirely new therapeutic modality. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article